Astra, Daiichi post late-stage data for Enhertu (AZN:NASDAQ)

Core Insights - AstraZeneca and Daiichi Sankyo announced positive data from two late-stage trials for their antitumor agent Enhertu, indicating its effectiveness in early breast cancer treatment [2] Company Summary - Enhertu is currently approved in the U.S. for certain cancer indications, and the new data may expand its use in early-stage breast cancer [2]